http://rdf.ncbi.nlm.nih.gov/pubchem/reference/31580388

Outgoing Links

Predicate Object
contentType Journal Article
endingPage 54
issn 1177-5483
issueIdentifier 2
pageRange 347-54
publicationName Clinical ophthalmology (Auckland, N.Z.)
startingPage 347
bibliographicCitation Sivaprasad S, Acharya N, Hykin P. Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK. Clin Ophthalmol. 2008 Jun;2(2):347–54. PMID: 19668726; PMCID: PMC2693996.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2f3e050dc82c7542e3e481d0d90eb4fe
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cecc0ec491c76969696a45f3c2064699
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8d704d7b58b6c928b1bfbcd9f006a132
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-8952-0659
date 200806
identifier https://pubmed.ncbi.nlm.nih.gov/19668726
https://doi.org/10.2147/opth.s2601
https://pubmed.ncbi.nlm.nih.gov/PMC2693996
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/35582
https://portal.issn.org/resource/ISSN/1177-5483
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8397
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5360545
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7671
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_714b3f52d8149c3277181d9513b93112
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10521
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID56603655

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128926582
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136090971
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127977452
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128684338
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128288886
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128797476

Total number of triples: 34.